Two more patients die in trial of Juno's JCAR015
Two more patients have died during a trial of Juno Therapeutics’ candidate white blood cell cancer therapy, JCAR015.
Two more patients have died during a trial of Juno Therapeutics’ candidate white blood cell cancer therapy, JCAR015.
A plan to attract advanced medicinal therapy manufacturing to the UK has emphasised the importance of the MHRA having a leading role in development of global regulatory standards.
While the temperature is dropping outside, keeping clinical trial therapeutics and biospecimens at the right temperature during transportation is a challenge year-round.
GlobeImmune has terminated the lease agreement on its manufacturing site after Gilead’s withdrew from a Phase II hepatitis B vaccine collaboration.